The New Rules for Mounjaro in the UK: Separating Fact from Rumour

The biggest misconception: that the new NICE guidance opened Mounjaro to everyone on the NHS

When NICE published its recommendation for tirzepatide in December 2024, many headlines read it as a green light for anyone with obesity to receive Mounjaro on the NHS. That is not what happened. NICE recommended tirzepatide (TA1026) for adults with a BMI of 35 or above and at least one weight-related comorbidity, through a phased NHS rollout, not as a medicine available on demand at your GP surgery.

NHS England set out a careful sequence. The first cohort, from June 2025, required a BMI of 40 or above plus four or more of five specific conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. Cohort 2 activated in June 2026, widening access to people with a BMI of 35–39.9 and the same four-condition threshold. A third cohort, expected around March 2027, will extend to those with a BMI of 40 or above and three qualifying conditions. You can read the full phased eligibility detail in NICE's appraisal of tirzepatide (TA1026).

So for most people who don't meet that still-narrow NHS bar, or who would rather not wait, the new rules haven't unlocked an NHS prescription. What they have done is confirm that tirzepatide is clinically robust enough to be recommended by the UK's medicines advisory body. For GP practices that have opted in under the new 2026/27 contract, participation is optional, so availability varies considerably by area and surgery.

What the rules actually say about private eligibility, and why it's different

A question our prescribers hear most weeks is: "Do the new NHS rules apply to me if I'm going private?" The answer is no. Private prescribing follows the medicine's licensed indications as set out in the Summary of Product Characteristics, not NICE's NHS-access criteria. The Mounjaro licence covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as prediabetes, type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea.

For some ethnic backgrounds, lower BMI thresholds apply under UK guidance, specifically a 2.5 kg/m² reduction for South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds. That adjustment is reflected in the eligibility criteria our prescribers apply when assessing each consultation. BMI alone has never been the whole picture: a prescriber reviews your full health history, current medicines, and any contraindications before any prescription is issued.

The cost landscape also shifted when Eli Lilly raised Mounjaro's UK list price from 1 September 2025, with the highest-dose pen rising from around £122 to around £330. If you want to understand how private treatment is priced and what should be included in any legitimate offer, the Mounjaro cost guide breaks it down clearly.

The contraception rule change, one of the most practically important updates

Buried inside the updated clinical guidance is a change that directly affects many people who take Mounjaro. Because tirzepatide slows gastric emptying, it can reduce how well an oral contraceptive pill is absorbed in the early weeks of treatment and after each dose increase. The MHRA and NHS now advise that women taking the pill should add a non-oral contraceptive method, such as condoms, for the first four weeks of starting Mounjaro and for four weeks after each upward dose step. NHS England's guidance on weight-management injections covers this in detail, alongside advice on HRT and surgery.

There is no equivalent MHRA warning for semaglutide (Wegovy) and the pill, this is specific to tirzepatide. It doesn't mean oral contraceptives stop working altogether, but the four-week window of reduced absorption is real enough that the guidance now names it explicitly. If you're considering practical guidance for starting Mounjaro, this is one of the first things to discuss with your prescriber, not leave until later.

HRT users should also know that NHS England advises considering transdermal forms (patches or gels) while on tirzepatide, for the same absorption reason. Tell your GP or prescriber what you're taking; this is precisely why a full medicine review happens before treatment begins.

What hasn't changed, and what to do next

Amid all the updates, several things remain exactly as they were. Mounjaro is still a prescription-only medicine. No legitimate source can supply it without a clinical assessment by a qualified prescriber. The treatment schedule still starts at 2.5mg (that lower dose exists to let your body adjust, not because a small starting amount produces results) and titration is managed by your prescriber, not self-directed. The Mounjaro overview page covers the full clinical picture if you want to understand how the medicine works before making any decision.

For people comparing tirzepatide with other options, the evidence base has also grown. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, reported greater average weight reduction with tirzepatide than with semaglutide 2.4mg over 72 weeks in adults with obesity. If that comparison matters to you, the pipeline medicines comparison page and the weight-loss treatments overview offer broader context. Newer treatments such as retatrutide and pemvidutide are in development, the pemvidutide versus tirzepatide page explains where the evidence currently sits.

If you're ready to find out whether you're eligible, a free consultation with one of our GPhC-registered prescribers is the clearest next step. Check your eligibility here, a real clinician, not software, reviews your answers the same day.